Jim Cramer Highlights Sanofi’s Bid for Dynavax

“Congratulations. You cognize that one’s done. They got that bully bid from Sanofi. I’m going to really spell retired determination and speech to them astir that… Well played, my friend.”

Stock marketplace information showing an upward trajectory. Photo by Burak The Weekender connected Pexels

Dynavax Technologies Corporation (NASDAQ:DVAX) is simply a biopharmaceutical institution that creates and sells precocious vaccines, including a specialized changeable for hepatitis B and a unsocial additive utilized to boost immune responses. On December 24, Sanofi (NASDAQ:SNY) announced that it is acquiring the institution for astir $2.2 billion. The woody involves a currency tender connection of $15.50 per share. The CEO of Dynavax Technologies Corporation (NASDAQ:DVAX), Ryan Spencer, commented:

“We judge Sanofi’s commercialized reach, improvement capabilities and committedness to evidence-based immunization volition amplify the accidental for HEPLISAV-B and our innovative pipeline to code important nationalist wellness needs, further advancing our ngo to assistance support the satellite against infectious disease. We are assured that this transaction – and the compelling worth it provides – is successful the champion interests of the Company and its stockholders.”

While we admit the imaginable of DVAX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the champion short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.